{"id":"NCT02584504","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-30","primaryCompletion":"2017-04-05","completion":"2018-01-09","firstPosted":"2015-10-22","resultsPosted":"2018-05-07","lastUpdate":"2019-01-23"},"enrollment":163,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Atorvastatin","otherNames":[]},{"type":"DRUG","name":"Non-statin Lipid-Modifying Therapy","otherNames":[]},{"type":"OTHER","name":"Diet Alone","otherNames":[]}],"arms":[{"label":"Alirocumab 150 mg Q4W","type":"EXPERIMENTAL"},{"label":"Alirocumab 150 mg Q2W","type":"EXPERIMENTAL"},{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab administration as add-on therapy to non-statin lipid modifying therapy (LMT) including diet therapy alone or the lowest strength of statin in comparison with placebo after 12 weeks of treatment in participants with hypercholesterolemia.\n\nSecondary Objective:\n\n* To evaluate the effect of two treatment regimens of alirocumab on other lipid parameters: apolipoprotein B (Apo-B), non-high-density lipoprotein cholesterol (non HDL-C), total cholesterol (TC), lipoprotein (a) (Lp\\[a\\]), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and apolipoprotein A-1 (Apo A-1).\n* To evaluate the safety and tolerability of alirocumab administration.\n* To evaluate the development of anti-alirocumab antibodies.\n* To evaluate the pharmacokinetic and pharmacodynamic profiles of alirocumab administration.\n* To evaluate the long-term safety in participants receiving open-label alirocumab administration.","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis","timeFrame":"From Baseline to Week 12","effectByArm":[{"arm":"Alirocumab 150 mg Q4W","deltaMin":-43.8,"sd":2.2},{"arm":"Alirocumab 150 mg Q2W","deltaMin":-70.1,"sd":2.3},{"arm":"Placebo Q2W","deltaMin":-4.3,"sd":2.2}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":5},"locations":{"siteCount":30,"countries":["Japan"]},"refs":{"pmids":["28623954","30509509"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Viral upper respiratory tract infection","Fall","Back pain","Pharyngitis","Non-cardiac chest pain"]}}